166 related articles for article (PubMed ID: 33250741)
21. Assessment of individual molecular response in chronic myeloid leukemia patients with atypical BCR-ABL1 fusion transcripts: recommendations by the EUTOS cooperative network.
Schäfer V; White HE; Gerrard G; Möbius S; Saussele S; Franke GN; Mahon FX; Talmaci R; Colomer D; Soverini S; Machova Polakova K; Cross NCP; Hochhaus A; Ernst T
J Cancer Res Clin Oncol; 2021 Oct; 147(10):3081-3089. PubMed ID: 33677711
[TBL] [Abstract][Full Text] [Related]
22. Sensitive quantitation of minimal residual disease in chronic myeloid leukemia using nanofluidic digital polymerase chain reaction assay.
Goh HG; Lin M; Fukushima T; Saglio G; Kim D; Choi SY; Kim SH; Lee J; Lee YS; Oh SM; Kim DW
Leuk Lymphoma; 2011 May; 52(5):896-904. PubMed ID: 21338281
[TBL] [Abstract][Full Text] [Related]
23. BCR-ABL1 expression, RT-qPCR and treatment decisions in chronic myeloid leukaemia.
Latham S; Bartley PA; Budgen B; Ross DM; Hughes E; Branford S; White D; Hughes TP; Morley AA
J Clin Pathol; 2016 Sep; 69(9):817-21. PubMed ID: 26837312
[TBL] [Abstract][Full Text] [Related]
24. Comparison of Real-Time Quantitative PCR and Digital Droplet PCR for BCR-ABL1 Monitoring in Patients with Chronic Myeloid Leukemia.
Franke GN; Maier J; Wildenberger K; Cross M; Giles FJ; Müller MC; Hochhaus A; Niederwieser D; Lange T
J Mol Diagn; 2020 Jan; 22(1):81-89. PubMed ID: 31669230
[TBL] [Abstract][Full Text] [Related]
25. Comparison of molecular responses based on BCR-ABL1% (IS) results from an in-house TaqMan-based qPCR versus Xpert(®) assay in CML patients on tyrosine kinase inhibitor therapy.
Boeckx N; Laer CV; Roover JD; Wilmsen B; Bruyninckx K; Pauwels S
Acta Clin Belg; 2015 Aug; 70(4):237-43. PubMed ID: 26166681
[TBL] [Abstract][Full Text] [Related]
26. BCR-ABL1 RT-qPCR for monitoring the molecular response to tyrosine kinase inhibitors in chronic myeloid leukemia.
Press RD; Kamel-Reid S; Ang D
J Mol Diagn; 2013 Sep; 15(5):565-76. PubMed ID: 23810242
[TBL] [Abstract][Full Text] [Related]
27. Assessment of Outcomes After Stopping Tyrosine Kinase Inhibitors Among Patients With Chronic Myeloid Leukemia: A Nonrandomized Clinical Trial.
Atallah E; Schiffer CA; Radich JP; Weinfurt KP; Zhang MJ; Pinilla-Ibarz J; Kota V; Larson RA; Moore JO; Mauro MJ; Deininger MWN; Thompson JE; Oehler VG; Wadleigh M; Shah NP; Ritchie EK; Silver RT; Cortes J; Lin L; Visotcky A; Baim A; Harrell J; Helton B; Horowitz M; Flynn KE
JAMA Oncol; 2021 Jan; 7(1):42-50. PubMed ID: 33180106
[TBL] [Abstract][Full Text] [Related]
28. Monitoring of Minimal Residual Disease (MRD) in Chronic Myeloid Leukemia: Recent Advances.
Cumbo C; Anelli L; Specchia G; Albano F
Cancer Manag Res; 2020; 12():3175-3189. PubMed ID: 32440215
[TBL] [Abstract][Full Text] [Related]
29. A new highly sensitive real-time quantitative-PCR method for detection of BCR-ABL1 to monitor minimal residual disease in chronic myeloid leukemia after discontinuation of imatinib.
Kitamura H; Tabe Y; Ai T; Tsuchiya K; Yuri M; Misawa S; Horii T; Kawaguchi A; Ohsaka A; Kimura S
PLoS One; 2019; 14(3):e0207170. PubMed ID: 30835732
[TBL] [Abstract][Full Text] [Related]
30. Quantitative real-time polymerase chain reaction as an efficient molecular tool for detecting minimal residual disease in Moroccan chronic myeloid leukemia patients.
Moumen A; Dehbi H; Kottwitz D; El Amrani M; Bouchoutrouch N; El Hadi H; Quessar A; Benchekroun S; Nadifi S; Sefrioui H
Genet Mol Res; 2015 Feb; 14(1):1044-55. PubMed ID: 25730044
[TBL] [Abstract][Full Text] [Related]
31. A Novel High-Throughput Method for Molecular Detection of Human Pathogenic Viruses Using a Nanofluidic Real-Time PCR System.
Coudray-Meunier C; Fraisse A; Martin-Latil S; Delannoy S; Fach P; Perelle S
PLoS One; 2016; 11(1):e0147832. PubMed ID: 26824897
[TBL] [Abstract][Full Text] [Related]
32. Comparison of Droplet Digital PCR versus qPCR Measurements on the International Scale for the Molecular Monitoring of Chronic Myeloid Leukemia Patients.
Cortés AA; Olmedillas S; Serrano-López J; Lainez-González D; Castaño T; Iñiguez R; Lopez-Lorenzo JL; García A; Atance M; Sánchez RNS; Lopez CB; Arranz MG; Sillero PL; Alonso-Dominguez JM
Mol Diagn Ther; 2020 Oct; 24(5):593-600. PubMed ID: 32875515
[TBL] [Abstract][Full Text] [Related]
33. Sensitive Replicate Real-Time Quantitative PCR of BCR-ABL Shows Deep Molecular Responses in Long-Term Post-Allogeneic Stem Cell Transplantation Chronic Myeloid Leukemia Patients.
Koren-Michowitz M; Shimoni A; Daraio F; Crasto F; Lorenzatti R; Volchek Y; Amariglio N; Gottardi E; Saglio G; Nagler A
Biol Blood Marrow Transplant; 2015 Oct; 21(10):1852-5. PubMed ID: 26151304
[TBL] [Abstract][Full Text] [Related]
34. Results of the European survey on the assessment of deep molecular response in chronic phase CML patients during tyrosine kinase inhibitor therapy (EUREKA registry).
Möbius S; Schenk T; Himsel D; Maier J; Franke GN; Saussele S; Pott C; Andrikovics H; Meggyesi N; Machova-Polakova K; Zizkova H; Jurcek T; Mesanovic S; Zadro R; Gottardi E; Haenig J; Schuld P; Cross NCP; Hochhaus A; Ernst T
J Cancer Res Clin Oncol; 2019 Jun; 145(6):1645-1650. PubMed ID: 30941573
[TBL] [Abstract][Full Text] [Related]
35. Economic value of regular monitoring of response to treatment among US patients with chronic myeloid leukemia based on an economic model.
Jabbour EJ; Siegartel LR; Lin J; Lingohr-Smith M; Menges B; Makenbaeva D
J Med Econ; 2018 Oct; 21(10):1036-1040. PubMed ID: 30071761
[TBL] [Abstract][Full Text] [Related]
36. Novel Multiplex Droplet Digital PCR Assays to Monitor Minimal Residual Disease in Chronic Myeloid Leukemia Patients Showing Atypical
Petiti J; Lo Iacono M; Dragani M; Pironi L; Fantino C; Rapanotti MC; Quarantelli F; Izzo B; Divona M; Rege-Cambrin G; Saglio G; Gottardi EM; Cilloni D; Fava C
J Clin Med; 2020 May; 9(5):. PubMed ID: 32414125
[No Abstract] [Full Text] [Related]
37. Sensitive detection and quantification of minimal residual disease in chronic myeloid leukaemia using nested quantitative PCR for BCR-ABL DNA.
Bartley PA; Ross DM; Latham S; Martin-Harris MH; Budgen B; Wilczek V; Branford S; Hughes TP; Morley AA
Int J Lab Hematol; 2010 Dec; 32(6 Pt 1):e222-8. PubMed ID: 20491997
[TBL] [Abstract][Full Text] [Related]
38. One-Step Multiplexed Droplet Digital Polymerase Chain Reaction for Quantification of p190 BCR-ABL1 Fusion Transcript in B-Lymphoblastic Leukemia.
Martinez RJ; Kang Q; Nennig D; Bailey NG; Brown NA; Betz BL; Tewari M; Thyagarajan B; Bachanova V; Mroz P
Arch Pathol Lab Med; 2022 Jan; 146(1):92-100. PubMed ID: 33769465
[TBL] [Abstract][Full Text] [Related]
39. A rare e13a3 (b2a3) BCR-ABL1 fusion transcript with normal karyotype in chronic myeloid leukemia: The challenges in diagnosis and monitoring minimal residual disease (MRD).
Duan MH; Li H; Cai H
Leuk Res; 2017 Aug; 59():8-11. PubMed ID: 28527402
[TBL] [Abstract][Full Text] [Related]
40. Molecular Monitoring of Chronic Myeloid Leukemia.
Dominy K; Mokretar K; Reid AG; Khorashad JS
Methods Mol Biol; 2020; 2065():153-173. PubMed ID: 31578694
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
